Physician profile

Amanda Daoud

Rancho Cucamonga, CA

NPI 1285253179

$358.49

in general payments reported to CMS, 2019-2025

6 companies · $163 in 2025

The $163 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$294.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Vector Surgical, LLC $131.67 2025
Kci USA, INC. $99.88 2023 Prevena
Smith+Nephew, INC. $48.24 2022
Astrazeneca Pharmaceuticals Lp $31.64 2025 Enhertu
Boston Scientific Corporation $31.49 2024 Sq-Rx Pulse Generator
Medtronic, INC. $15.57 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amanda Daoud

$358.49

in general payments reported 2019-2025

Years
2022-2025
Top company
Vector Surgical, LLC
Context
The $163 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11421680/amanda-daoud

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.